Axcella is a biotech company using endogenous metabolic modulator compositions to treat complex diseases. Their product candidates reset biological pathways, improve cellular energetics, and restore homeostasis. They have lead therapeutic candidates in Phase 2 development for hepatic encephalopathy, Long COVID, and NASH. Axcella's unique model allows for evaluation through non-IND clinical studies or IND clinical trials.